|
1
|
Wang MC and Lloyd-Jones DM: Cardiovascular
risk assessment in hypertensive patients. Am J Hypertens.
34:569–577. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Małyszko J, Małyszko M, Kozlowski L,
Kozlowska K and Małyszko J: Hypertension in malignancy-an
underappreciated problem. Oncotarget. 9:20855–20871. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Raimondi S, Botteri E, Munzone E, Cipolla
C, Rotmensz N, DeCensi A and Gandini S: Use of beta-blockers and
angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers and breast cancer survival: Systematic review and
meta-analysis. Int J Cancer. 139:212–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Deng Y, Xie Y, Wang M, Xu P, Wei B, Li N,
Wu Y, Yang S, Zhou L, Hao Q, et al: Effects of antihypertensive
drugs use on risk and prognosis of colorectal cancer: A
meta-analysis of 37 observational studies. Front Pharmacol.
12:6706572022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Allen AM: Role of angiotensin in the
rostral ventrolateral medulla in the development and maintenance of
hypertension. Curr Opin Pharmacol. 11:117–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dinh DT, Frauman AG, Johnston CI and
Fabiani ME: Angiotensin receptors: Distribution, signalling and
function. Clin Sci (Lond). 100:481–492. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arendse LB, Danser AHJ, Poglitsch M, Touyz
RM, Burnett JC Jr, Llorens-Cortes C, Ehlers MR and Sturrock ED:
Novel therapeutic approaches targeting the renin-angiotensin system
and associated peptides in hypertension and heart failure.
Pharmacol Rev. 71:539–570. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Escobar E, Rodríguez-Reyna TS, Arrieta O
and Sotelo J: Angiotensin II and cell proliferation and
angiogenesis regulator: Biologic and therapeutic implications in
cancer. Curr Vasc Pharmacol. 2:385–399. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ram CV: Antihypertensive drugs: An
overview. Am J Cardiovasc Drugs. 2:77–89. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neo JH, Malcontenti-Wilson C, Muralidharan
V and Christophi C: Effect of ACE inhibitors and angiotensin II
receptor antagonists in a mouse model of colorectal cancer liver
metastases. J Gastroenterol Hepatol. 22:577–584. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pfeffer MA, Swedberg K, Granger CB, Held
P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S and
Pocock S; CHARM Investigators Committees, : Effects of candesartan
on mortality and morbidity in patients with chronic heart failure:
The CHARM-Overall programme. Lancet. 362:759–766. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tamburrino D, Guarneri G, Partelli S,
Crippa S, Falconi M and Capurso G: Does chronic consumption of
angiotensin-converting enzyme inhibitors affect survival after
surgical resection of pancreatic ductal adenocarcinoma? Dig Liver
Dis. 53:1065–1067. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Higgins JPT and Green S: Cochrane handbook
for systematic reviews of interventions. Version 5.1.0 [Updated
March 2011]. The Cochrane Collaboration. 2011.Available from.
www.handbook.cochrane.org
|
|
15
|
Moher D, Liberati A, Tetzlaff J and Altman
DG; PRISMA Group, : Preferred reporting items for systematic
reviews and meta-analyses: The PRISMA statement. PLoS Med.
6:e10000972009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wells GA, Shea B, O'Connell D, Peterson J,
Welch V, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for assessing the quality if nonrandomized studies in
meta-analyses. Available from URL:. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm[cited
2009 Oct 19].
|
|
17
|
Anderson JL, Knowlton KU, Muhlestein JB,
Bair TL, Le VT and Horne BD: Evaluation of treatment with
angiotensin converting enzyme inhibitors and the risk of lung
cancer: ERACER-an observational cohort study. J Cardiovasc
Pharmacol Ther. 26:321–327. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aydiner A, Ciftci R and Sen F:
Renin-angiotensin system blockers may prolong survival of
metastatic non-small cell lung cancer patients receiving erlotinib.
Medicine (Baltimore). 94:e8872015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Balkrishnan R, Desai RP, Narayan A,
Camacho FT, Flausino LE and Chammas R: Associations between
initiating antihypertensive regimens on stage I–III colorectal
cancer outcomes: A medicare SEER cohort analysis. Cancer Med.
10:5347–5357. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Botteri E, Munzone E, Rotmensz N, Cipolla
C, De Giorgi V, Santillo B, Zanelotti A, Adamoli L, Colleoni M,
Viale G, et al: Therapeutic effect of β-blockers in triple-negative
breast cancer postmenopausal women. Breast Cancer Res Treat.
140:567–575. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Busby J, McMenamin Ú, Spence A, Johnston
BT, Hughes C and Cardwell CR: Angiotensin receptor blocker use and
gastro-oesophageal cancer survival: A population-based cohort
study. Aliment Pharmacol Ther. 47:279–288. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cardwell CR, Mc Menamin ÚC, Hicks BM,
Hughes C, Cantwell MM and Murray LJ: Drugs affecting the
renin-angiotensin system and survival from cancer: A population
based study of breast, colorectal and prostate cancer patient
cohorts. BMC Med. 12:282014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chae YK, Brown EN, Lei X, Melhem-Bertrandt
A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM and
Chavez-Macgregor M: Use of ACE inhibitors and angiotensin receptor
blockers and primary breast cancer outcomes. J Cancer. 4:549–556.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho MA, Jeong SY, Sohn I, Kim MS, Kang JH,
Paik ES, Lee YY and Choi CH: Impact of angiotensin receptor
blockers, beta blockers, calcium channel blockers and thiazide
diuretics on survival of ovarian cancer patients. Cancer Res Treat.
52:645–654. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui Y, Wen W, Zheng T, Li H, Gao YT, Cai
H, You M, Gao J, Yang G, Zheng W, et al: Use of antihypertensive
medications and survival rates for breast, colorectal, lung, or
stomach cancer. Am J Epidemiol. 188:1512–1528. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Engineer DR, Burney BO, Hayes TG and
Garcia JM: Exposure to ACEI/ARB and β-blockers is associated with
improved survival and decreased tumor progression and
hospitalizations in patients with advanced colon cancer. Transl
Oncol. 6:539–545. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eskelinen T, Veitonmäki T, Kotsar A,
Tammela TLJ, Pöyhönen A and Murtola TJ: Improved renal cancer
prognosis among users of drugs targeting renin-angiotensin system.
Cancer Causes Control. 33:313–320. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fiala O, Ostasov P, Sorejs O, Liska V,
Buchler T, Poprach A and Finek J: Incidental use of beta-blockers
is associated with outcome of metastatic colorectal cancer patients
treated with bevacizumab-based therapy: A single-institution
retrospective analysis of 514 patients. Cancers (Basel).
11:18562019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fiala O, Ostašov P, Rozsypalová A, Hora M,
Šorejs O, Šustr J, Bendová B, Trávníček I, Filipovský J, Fínek J
and Büchler T: Impact of concomitant cardiovascular medication on
survival of metastatic renal cell carcinoma patients treated with
sunitinib or pazopanib in the first line. Target Oncol. 16:643–652.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fryzek JP, Poulsen AH, Johnsen SP,
McLaughlin JK, Sørensen HT and Friis S: A cohort study of
antihypertensive treatments and risk of renal cell cancer. Br J
Cancer. 92:1302–1306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ganz PA, Habel LA, Weltzien EK, Caan BJ
and Cole SW: Examining the influence of beta blockers and ACE
inhibitors on the risk for breast cancer recurrence: Results from
the LACE cohort. Breast Cancer Res Treat. 129:549–556. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harding BN, Delaney JA, Urban RR and Weiss
NS: Post-diagnosis use of antihypertensive medications and the risk
of death from ovarian cancer. Gynecol Oncol. 154:426–431. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Holmes S, Griffith EJ, Musto G and Minuk
GY: Antihypertensive medications and survival in patients with
cancer: A population-based retrospective cohort study. Cancer
Epidemiol. 37:881–885. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang T, Townsend MK, Dood RL, Sood AK and
Tworoger SS: Antihypertensive medication use and ovarian cancer
survival. Gynecol Oncol. 163:342–347. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Keith SW, Maio V, Arafat HA, Alcusky M,
Karagiannis T, Rabinowitz C, Lavu H and Louis DZ: Angiotensin
blockade therapy and survival in pancreatic cancer: A population
study. BMC Cancer. 22:1502022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Keizman D, Huang P, Eisenberger MA, Pili
R, Kim JJ, Antonarakis ES, Hammers H and Carducci MA: Angiotensin
system inhibitors and outcome of sunitinib treatment in patients
with metastatic renal cell carcinoma: A retrospective examination.
Eur J Cancer. 47:1955–1961. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim ST, Park KH, Oh SC, Seo JH, Kim JS,
Shin SW and Kim YH: How does inhibition of the renin-angiotensin
system affect the prognosis of advanced gastric cancer patients
receiving platinum-based chemotherapy? Oncology. 83:354–360. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Iede K, Yamada T, Ueda M, Tsuda Y,
Nakashima S, Ohta K, Tanida T, Matsuyama J, Ikenaga M and Tominaga
S: Do antihypertensive drugs really have antitumor effects?
Baseline differences in hypertensive and non-hypertensive patients
with advanced pancreatic cancer. Medicine (Baltimore).
101:e295322022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li PC, Huang RY, Yang YC, Hsieh KP and
Yang YH: Prognostic impact of angiotensin-converting enzyme
inhibitors and angiotensin receptors blockers in esophageal or
gastric cancer patients with hypertension-a real-world study. BMC
Cancer. 22:4302022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin YT, Wang HC, Tsai MH, Su YY, Yang MY
and Chien CY: Angiotensin II receptor blockers valsartan and
losartan improve survival rate clinically and suppress tumor growth
via apoptosis related to PI3K/AKT signaling in nasopharyngeal
carcinoma. Cancer. 127:1606–1619. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lorona NC, Cook LS, Tang MTC, Hill DA,
Wiggins CL and Li CI: Antihypertensive medications and risks of
recurrence and mortality in luminal, triple-negative, and
HER2-overexpressing breast cancer. Cancer Causes Control.
32:1375–1384. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mafiana RN, Al-Kindi MS, Mafiana N, Al
Lawati AS and Al Moundhri M: Impact of metabolic syndrome diagnosis
and its treatment on survival of colorectal cancer patients. J
Cancer Epidemiol. 2019:65274572019.PubMed/NCBI
|
|
43
|
Ho CM, Lee CH, Lee MC, Zhang JF, Wang JY,
Hu RH and Lee PH: Comparative effectiveness of
angiotensin-converting enzyme inhibitors and angiotensin II
receptor blockers in chemoprevention of hepatocellular carcinoma: A
nationwide high-risk cohort study. BMC Cancer. 18:4012018.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Morris ZS, Saha S, Magnuson WJ, Morris BA,
Borkenhagen JF, Ching A, Hirose G, McMurry V, Francis DM, Harari
PM, et al: Increased tumor response to neoadjuvant therapy among
rectal cancer patients taking angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers. Cancer. 122:2487–2495.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nakai Y, Isayama H, Ijichi H, Sasaki T,
Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y,
et al: Inhibition of renin-angiotensin system affects prognosis of
advanced pancreatic cancer receiving gemcitabine. Br J Cancer.
103:1644–1648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Nakai Y, Isayama H, Sasaki T, Takahara N,
Saito K, Ishigaki K, Hamada T, Mizuno S, Miyabayashi K, Yamamoto K,
et al: The inhibition of renin-angiotensin system in advanced
pancreatic cancer: An exploratory analysis in 349 patients. J
Cancer Res Clin Oncol. 141:933–939. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nayan M, Juurlink DN, Austin PC, Macdonald
EM, Finelli A, Kulkarni GS and Hamilton RJ: Canadian Drug Safety
and Effectiveness Research Network (CDSERN): Medication use and
kidney cancer survival: A population-based study. Int J Cancer.
142:1776–1785. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Osumi H, Matsusaka S, Wakatsuki T, Suenaga
M, Shinozaki E and Mizunuma N: Angiotensin II type-1 receptor
blockers enhance the effects of bevacizumab-based chemotherapy in
metastatic colorectal cancer patients. Mol Clin Oncol. 3:1295–1300.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ozawa T, Hashiguchi Y, Yagi T, Fukushima
Y, Shimada R, Hayama T, Tsuchiya T, Nozawa K, Iinuma H, Ishihara S
and Matsuda K: Angiotensin I-converting enzyme
inhibitors/angiotensin II receptor blockers may reduce tumor
recurrence in left-sided and early colorectal cancers. Int J
Colorectal Dis. 34:1731–1739. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Santala EEE, Kotsar A, Veitonmäki T,
Tammela TLJ and Murtola TJ: Risk of urothelial cancer death among
people using antihypertensive drugs-a cohort study from Finland.
Scand J Urol. 53:185–192. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Santala EEE, Murto MO, Artama M, Pukkala
E, Visvanathan K and Murtola TJ: Angiotensin receptor blockers
associated with improved breast cancer survival-a nationwide cohort
study from Finland. Cancer Epidemiol Biomarkers Prev. 29:2376–2382.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Santala EE, Rannikko A and Murtola TJ:
Antihypertensive drugs and prostate cancer survival after radical
prostatectomy in Finland-A nationwide cohort study. Int J Cancer.
144:440–447. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Siltari A, Murtola TJ, Talala K, Taari K,
Tammela TLJ and Auvinen A: Antihypertensive drug use and prostate
cancer-specific mortality in Finnish men. PLoS One.
15:e02342692020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Santala EEE, Artama M, Pukkala E,
Visvanathan K, Staff S and Murtola TJ: Antihypertensive drug use
and the risk of ovarian cancer death among Finnish ovarian cancer
patients-a nationwide cohort study. Cancers (Basel). 13:20872021.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Siltari A, Murtola TJ, Talala K, Taari K,
Tammela TLJ and Auvinen A: Antihypertensive drugs and prostate
cancer risk in a Finnish population-based cohort. Scand J Urol.
52:321–327. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Støer NC, Bouche G, Pantziarka P, Sloan
EK, Andreassen BK and Botteri E: Use of non-cancer drugs and
survival among patients with pancreatic adenocarcinoma: A
nationwide registry-based study in Norway. Acta Oncol.
60:1146–1153. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Stokes WA, Molina E, McDermott JD, Morgan
RL, Bickett T, Fakhoury KR, Amini A and Karam SD: Survival impact
of angiotensin-converting enzyme inhibitors and angiotensin II
receptor antagonists in head and neck cancer. Head Neck.
43:3255–3275. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wilk M, Waśko-Grabowska A, Skoneczna I and
Szmit S: Angiotensin system inhibitors may improve outcomes of
patients with castration-resistant prostate cancer during
abiraterone acetate treatment-a cardio-oncology study. Front Oncol.
11:6647412021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wilop S, von Hobe S, Crysandt M, Esser A,
Osieka R and Jost E: Impact of angiotensin I converting enzyme
inhibitors and angiotensin II type 1 receptor blockers on survival
in patients with advanced non-small-cell lung cancer undergoing
first-line platinum-based chemotherapy. J Cancer Res Clin Oncol.
135:1429–1435. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wu CN, Wu SC, Chen WC, Yang YH, Chin JC,
Chien CY, Fang FM, Li SH, Luo SD and Chiu TJ: Angiotensin II
receptor blockers and oral squamous cell carcinoma survival: A
propensity-score-matched cohort study. PLoS One. 16:e02607722021.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yoshida T, Kinoshita H, Fukui K, Matsuzaki
T, Yoshida K, Mishima T, Yanishi M, Komai Y, Sugi M, Inoue T, et
al: Prognostic impact of renin-angiotensin inhibitors in patients
with bladder cancer undergoing radical cystectomy. Ann Surg Oncol.
24:823–831. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zhang Y, Song M, Chan AT, Meyerhardt JA,
Willett WC and Giovannucci EL: Long-term use of antihypertensive
medications and hypertension and colorectal cancer risk mortality:
A prospective cohort study. Br J Cancer. 127:1974–1982. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang A, Wu H, Lau ESH, Shi M, Fan B, Kong
APS, Ma RCW, Luk AOY, Chan JCN and Chow E: Effects of RAS
inhibitors on all-site cancers and mortality in the Hong Kong
diabetes surveillance database (2002–2019). EBioMedicine.
83:1042192022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Israili ZH, Hernández-Hernández R and
Valasco M: The future of antihypertensive treatment. Am J Ther.
14:121–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li XY, Sun JF and Hu SQ: The
renin-angiotensin system blockers as adjunctive therapy for cancer:
A meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci.
21:1375–1383. 2017.PubMed/NCBI
|
|
66
|
Deshayes F and Nahmias C: Angiotensin
receptors: A new role in cancer? Trends Endocrinol Metab.
16:293–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Mc Menamin ÚC, Murray LJ, Cantwell MM and
Hughes CM: Angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers in cancer progression and survival: A systematic
review. Cancer Causes Control. 23:221–230. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li J, Lam ASM, Yau STY, Yiu KKL and Tsoi
KKF: Antihypertensive treatments and risks of lung cancer: A large
population-based cohort study in Hong Kong. BMC Cancer.
21:12022021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mehrdad SA, Mirzavi F, Seyedi SMR and
Asoodeh A: The effect of angiotensin receptor blockers and
angiotensin-converting enzyme inhibitors on progression of gastric
cancer: Systematic review and meta-analysis. Anticancer Drugs.
33:983–988. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Te Riet L, van Esch JH, Roks AJ, van den
Meiracker AH and Danser AH: Hypertension:
renin-angiotensin-aldosterone system alterations. Circ Res.
116:960–975. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Timmermans PB, Wong PC, Chiu AT, Herblin
WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA and Smith RD:
Angiotensin II receptors and angiotensin II receptor antagonists.
Pharmacol Rev. 45:205–251. 1993.PubMed/NCBI
|
|
72
|
Burnier M: Angiotensin II type 1 receptor
blockers. Circulation. 103:904–912. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hassani B, Attar Z and Firouzabadi N: The
renin-angiotensin-aldosterone system (RAAS) signaling pathways and
cancer: Foes versus allies. Cancer Cell Int. 23:2542023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Imai N, Hashimoto T, Kihara M, Yoshida S,
Kawana I, Yazawa T, Kitamura H and Umemura S: Roles for host and
tumor angiotensin II type 1 receptor in tumor growth and
tumor-associated angiogenesis. Lab Invest. 87:189–198. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Judd SJ, Alderman J, Bowden J and
Michailov L: Evidence against the involvement of opiate neurons in
mediating the effect of clomiphene citrate on
gonadotropin-releasing hormone neurons. Fertil Steril. 47:574–578.
1987. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pei N, Mao Y, Wan P, Chen X, Li A, Chen H,
Li J, Wan R, Zhang Y, Du H, et al: Angiotensin II type 2 receptor
promotes apoptosis and inhibits angiogenesis in bladder cancer. J
Exp Clin Cancer Res. 36:772017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Xu J, Fan J, Wu F, Huang Q, Guo M, Lv Z,
Han J, Duan L, Hu G, Chen L, et al: The ACE2/angiotensin-(1–7)/Mas
receptor axis: Pleiotropic roles in cancer. Front Physiol.
8:2762017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ferreira AJ and Santos RA: Cardiovascular
actions of angiotensin-(1–7). Braz J Med Biol Res. 38:499–507.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Rhodes DR, Ateeq B, Cao Q, Tomlins SA,
Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE,
Bhojani MS, et al: AGTR1 overexpression defines a subset of breast
cancer and confers sensitivity to losartan, an AGTR1 antagonist.
Proc Natl Acad Sci USA. 106:10284–10289. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Weigelt B, Geyer FC and Reis-Filho JS:
Histological types of breast cancer: How special are they? Mol
Oncol. 4:192–208. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Harbeck N and Gnant M: Breast cancer.
Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Cushman DW and Ondetti MA: History of the
design of captopril and related inhibitors of angiotensin
converting enzyme. Hypertension. 17:589–592. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Burch RM, Farmer SG and Steranka LR:
Bradykinin receptor antagonists. Med Res Rev. 10:237–269. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Montana V and Sontheimer H: Bradykinin
promotes the chemotactic invasion of primary brain tumors. J
Neurosci. 31:4858–4867. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Cheng CY, Kuo CT, Lin CC, Hsieh HL and
Yang CM: IL-1beta induces expression of matrix metalloproteinase-9
and cell migration via a c-Src-dependent, growth factor receptor
transactivation in A549 cells. Br J Pharmacol. 160:1595–1610. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Yu HS, Lin TH and Tang CH: Involvement of
intercellular adhesion molecule-1 up-regulation in bradykinin
promotes cell motility in human prostate cancers. Int J Mol Sci.
14:13329–13345. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hill RD and Vaidya PN: Angiotensin II
receptor blockers (ARB). StatPearls [Internet]. StatPearls
Publishing; Treasure Island, FL: 2024
|
|
88
|
Piepho RW: Overview of the
angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm.
57 (Suppl 1):S3–S7. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Colin M, Delaitre C, Foulquier S and
Dupuis F: The AT1/AT2 receptor equilibrium is
a cornerstone of the regulation of the renin angiotensin system
beyond the cardiovascular system. Molecules. 28:54812023.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Kidoguchi S, Sugano N, Yokoo T, Kaneko H,
Akazawa H, Mukai M, Node K, Yano Y and Nishiyama A:
Antihypertensive drugs and cancer risk. Am J Hypertens. 35:767–783.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Tsioufis C and Thomopoulos C: Combination
drug treatment in hypertension. Pharmacol Res. 125:266–271. 2017.
View Article : Google Scholar : PubMed/NCBI
|
